Saturday, 21 November 2026NewsWorldBusinessTech
Latest

Kumamoto University Study Finds Lenacapavir Creates Giant Noninfectious HIV Particles

Lenacapavir binds to mature capsid proteins and their precursor Gag on September 3, 2026, creating giant noninfectious virus particles, according to the Proceedings of the National Academy of Sciences.

Researchers investigated how the drug influences human immunodeficiency virus type 1 during the terminal phase of its replication cycle, Medical Xpress reported. The long-acting antiretroviral medication is established for preventing and treating human immunodeficiency virus infection by blocking early post-entry replication steps.

The research was conducted through a joint collaboration involving Kumamoto University, Hamamatsu University School of Medicine, the University of Miyazaki, the National Hospital Organization Nagoya Medical Center, and Tokyo University of Technology, Technology Networks reported.

Specifically, the institutions involved include the Department of Microbiology within the Faculty of Life Sciences at Kumamoto University, the Department of Infectious Diseases and Immunology at the Clinical Research Center of NHO Nagoya Medical Center, the Laboratory for Evolutionary Cell Biology of the Skin within the School of Bioscience and Biotechnology at Tokyo University of Technology, and the Frontier Science Research Center at the University of Miyazaki, according to the study details.

Typical human immunodeficiency virus type 1 virions assemble into uniform, spherical particles measuring roughly 100 to 130 nanometers in diameter under baseline conditions without the antiretroviral agent.

Kumamoto University Study Finds Lenacapavir Creates Giant Noninfectious HIV Particles
Photo: happeningnow.news

The investigators found that the drug binds directly to the Gag precursor as well as the mature capsid protein. The precursor and mature proteins possess distinct structural conformations and molecular assembly states.

The authors of the study, titled “Lenacapavir binding to immature Gag induces giant virions and causes protease-dependent inhibition of viral release,” include Wright Andrews Ofotsu Amesimeku, Yoshihiro Nakata, and Nami Monde, among a total of sixteen authors.

“An important and unexpected finding of our study is that lenacapavir can bind to both precursor Gag and mature Gag, despite differences in their structures and assembly states,” said Kazuaki Monde, a lecturer at Kumamoto University.

This binding to the Gag precursor disrupted orderly particle construction. Excessive intracellular Gag processing by the viral protease was observed in the presence of the drug, which contributed to impaired viral release.

refill of liquid on tubes
Photo: EATG

The compound also induced numerous abnormal, discrete clusters of Gag at the plasma membrane, creating heterogeneous lenacapavir-induced virus-like particles exceeding 200 nanometers in diameter that contained both Gag and envelope glycoproteins, Wright Andrews Ofotsu Amesimeku et al. wrote in their PNAS study.

The findings indicate that lenacapavir interferes with human immunodeficiency virus at more than one stage of its life cycle.

Kumamoto University traces its roots to 1756 with the founding of Saishunkan, a domain school, and Banjien, established by daimyō Shigekata Hosokawa. Chartered as a national university on May 31, 1949, it merged five institutions including Kumamoto Medical College (1896) and the Fifth High School (1887), a major center of western learning in the Meiji era.

The university now operates seven faculties and eight graduate schools with roughly 10,000 students, and its Honjo-kuhonji campus hosts the Center for AIDS Research alongside the Faculty of Life Sciences where this study was based.

The researchers hope these insights will help guide the development of improved capsid-targeting drugs and next-generation human immunodeficiency virus treatments.